Scarica l'app Stockscreener
26.83
4.79%
-1.35
Dopo l'orario di chiusura:
27.03
0.20
+0.75%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$28.18
Aprire:
$28.25
Volume 24 ore:
647.82K
Relative Volume:
1.01
Capitalizzazione di mercato:
$481.26M
Reddito:
$116.88M
Utile/perdita netta:
$-25.09M
Rapporto P/E:
-191.64
EPS:
-0.14
Flusso di cassa netto:
$-20.74M
1 W Prestazione:
-7.16%
1M Prestazione:
-29.32%
6M Prestazione:
+60.85%
1 anno Prestazione:
+73.88%
Intervallo 1D:
$26.53
$28.61
Intervallo di 1 settimana:
$26.53
$30.60
Portata 52W:
$13.57
$43.72
Rigel Pharmaceuticals Stock (RIGL) Company Profile
Nome
Rigel Pharmaceuticals
Settore
Industria
Telefono
650-624-1100
Indirizzo
611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA
Confronta RIGL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RIGL
Rigel Pharmaceuticals
|
26.83 | 505.47M | 116.88M | -25.09M | -20.74M | -0.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Rigel Pharmaceuticals Stock (RIGL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-04-03 | Ripresa | Piper Sandler | Neutral |
| 2022-06-09 | Downgrade | Citigroup | Buy → Neutral |
| 2022-06-08 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2022-06-08 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-03-23 | Iniziato | B. Riley Securities | Neutral |
| 2020-11-09 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-11-15 | Ripresa | Cantor Fitzgerald | Overweight |
| 2019-09-26 | Ripresa | JP Morgan | Overweight |
| 2019-03-01 | Reiterato | Cantor Fitzgerald | Overweight |
| 2018-08-27 | Iniziato | Citigroup | Buy |
| 2018-05-02 | Reiterato | Cantor Fitzgerald | Overweight |
| 2017-12-21 | Ripresa | Piper Jaffray | Overweight |
| 2017-12-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2017-11-06 | Ripresa | H.C. Wainwright | Buy |
| 2017-03-09 | Reiterato | H.C. Wainwright | Buy |
| 2016-08-31 | Reiterato | H.C. Wainwright | Buy |
| 2016-08-30 | Reiterato | Piper Jaffray | Overweight |
| 2016-07-13 | Iniziato | H.C. Wainwright | Buy |
| 2016-06-13 | Iniziato | Piper Jaffray | Overweight |
| 2016-04-22 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2013-04-08 | Reiterato | Stifel | Buy |
| 2012-11-29 | Iniziato | UBS | Neutral |
| 2012-11-06 | Reiterato | Oppenheimer | Outperform |
| 2012-03-26 | Iniziato | Canaccord Genuity | Hold |
| 2010-12-10 | Downgrade | MP Advisors | Outperform → Market Perform |
Mostra tutto
Rigel Pharmaceuticals Borsa (RIGL) Ultime notizie
Can Rigel Pharmaceuticals Inc. stock deliver strong Q4 earningsJuly 2025 Breakouts & Expert-Curated Trade Recommendations - newser.com
Is this a good reentry point in Rigel Pharmaceuticals Inc.July 2025 Movers & Verified Chart Pattern Trade Signals - newser.com
Is Rigel Pharmaceuticals Inc. stock a contrarian buy2025 Trading Volume Trends & Free Weekly Chart Analysis and Trade Guides - newser.com
What the charts say about Rigel Pharmaceuticals Inc. todayWeekly Investment Summary & Low Risk High Reward Trade Ideas - newser.com
Why Rigel Pharmaceuticals Inc. stock could see breakout soonMarket Performance Summary & Low Risk Investment Opportunities - newser.com
Rigel Pharmaceuticals Inc. stock volume spike explained2025 Fundamental Recap & Short-Term High Return Strategies - newser.com
Is Rigel Pharmaceuticals Inc. stock recession proofWatch List & Weekly Breakout Stock Alerts - newser.com
How Rigel Pharmaceuticals’ R289 Trial Progress and FDA Designations Will Impact RIGL Investors - Yahoo Finance
Rigel Pharmaceuticals (RIGL): Assessing Valuation Following Key Clinical Milestone for R289 - simplywall.st
Did Rigel's (RIGL) R289 Phase 1b Expansion Just Shift the Company's Pipeline Prospects? - simplywall.st
Is Rigel Pharmaceuticals Inc. stock reversal real or fakeMarket Trend Report & Safe Capital Growth Tips - newser.com
Rigel Pharmaceuticals (NASDAQ:RIGL) Receives "Hold (C+)" Rating from Weiss Ratings - MarketBeat
Rigel Pharmaceuticals stock advances as first patient enrolled in R289 study expansion - Investing.com
Multi factor analysis applied to Rigel Pharmaceuticals Inc.2025 Volume Leaders & Reliable Entry Point Alerts - newser.com
Published on: 2025-10-09 05:05:12 - newser.com
HC Wainwright & Co. Reiterates Rigel Pharmaceuticals (RIGL) Buy Recommendation - Nasdaq
H.C. Wainwright Maintains Rigel Pharmaceuticals(RIGL.US) With Buy Rating, Maintains Target Price $57 - 富途牛牛
Rigel Pharmaceuticals (NASDAQ:RIGL) Stock Price Down 4%What's Next? - MarketBeat
Rigel Pharmaceuticals (RIGL) Rating Reiterated as 'Buy' by HC Wa - GuruFocus
Rigel Pharmaceuticals' (RIGL) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Rigel Pharmaceuticals, Inc. Announces First Patient Enrolled in the Dose Expansion Phase of its Phase 1b Study of R289 in Patients with Lower-Risk MDS - MarketScreener
Rigel Pharmaceuticals (RIGL) Advances Phase 1b Study with New Pa - GuruFocus
Rigel announces first patient enrolled in dose expansion phase of 1b study of R289 in patients with lower-risk MDS - MarketScreener
Rigel Pharmaceuticals (NASDAQ:RIGL) Downgraded to "Hold" Rating by Zacks Research - MarketBeat
First patient enrolled: Rigel advances R289 Phase 1b dose expansion, 500 mg qd/bid, up to 40 pts for RP2D - Stock Titan
Does Rigel Pharmaceuticals Inc. qualify in momentum factor screening2025 Market WrapUp & Fast Momentum Stock Entry Tips - newser.com
Will Rigel Pharmaceuticals Inc. (RI2) stock profit from fiscal stimulusWeekly Profit Report & Expert Approved Momentum Trade Ideas - newser.com
Analyzing Rigel Pharmaceuticals Inc. with multi timeframe chartsWeekly Trend Recap & Free Technical Pattern Based Buy Signals - newser.com
Applying Elliott Wave Theory to Rigel Pharmaceuticals Inc.Fed Meeting & Proven Capital Preservation Methods - newser.com
Using portfolio simulators with Rigel Pharmaceuticals Inc. included2025 Bull vs Bear & High Return Trade Opportunity Guides - newser.com
Volume spikes in Rigel Pharmaceuticals Inc. stock – what they mean2025 Stock Rankings & Expert Curated Trade Setups - newser.com
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Eastern Progress
Immune Thrombocytopenic Purpura (ITP) Pipeline 2025: Pioneering Clinical Developments by 30+ Global Leaders – DelveInsight | Featuring Sanofi, Takeda, Rigel Pharmaceuticals, Bristol-Myers Squibb - Barchart.com
Rigel Pharmaceuticals announces inducement grants - MarketScreener
A Deep Dive Into Rigel Pharmaceuticals (RIGL) Valuation After Voya Investment Management Expands Stake - simplywall.st
Rigel Pharmaceuticals (NASDAQ:RIGL) Stock Price Crosses Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat
41,138 Options & 27,475 RSUs — Rigel Announces Inducement Grants to New Employees - Stock Titan
What analysts say about Rigel Pharmaceuticals Inc RI2 stockStock Buyback Updates & Free Rapid Wealth Multiplication - earlytimes.in
Voya Strengthens Position in Rigel Pharmaceuticals, Inc. (RIGL) - Insider Monkey
Can Rigel Pharmaceuticals Inc. (RI2) stock double in coming yearsJuly 2025 EndofMonth & Real-Time Stock Movement Alerts - newser.com
Can RIGL's Oncology Portfolio Create Long-Term Value Beyond Tavalisse? - sharewise.com
Should Value Investors Buy Rigel Pharmaceuticals (RIGL) Stock? - Yahoo Finance
Rigel Pharmaceuticals Azioni (RIGL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Rigel Pharmaceuticals Azioni (RIGL) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Schorno Dean L | EVP & Chief Financial Officer |
Feb 05 '25 |
Sale |
21.93 |
1,734 |
38,020 |
57,235 |
| Santos David A | EVP, Chief Commercial Officer |
Feb 04 '25 |
Sale |
20.92 |
2,125 |
44,457 |
53,500 |
| Santos David A | EVP, Chief Commercial Officer |
Feb 05 '25 |
Sale |
21.93 |
1,796 |
39,379 |
51,704 |
| RODRIGUEZ RAUL R | CEO, President |
Feb 04 '25 |
Sale |
20.92 |
4,952 |
103,601 |
243,854 |
| RODRIGUEZ RAUL R | CEO, President |
Feb 05 '25 |
Sale |
21.93 |
4,400 |
96,474 |
239,454 |
| Furey Raymond J. | EVP, GC, CCO & Corp Sec |
Feb 04 '25 |
Sale |
20.92 |
1,448 |
30,294 |
40,169 |
| Furey Raymond J. | EVP, GC, CCO & Corp Sec |
Feb 05 '25 |
Sale |
21.93 |
1,339 |
29,359 |
38,830 |
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):